Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Orthomyxoviridae Infections

ClinicalTrials.gov lists 2,195 trials for Orthomyxoviridae Infections or a narrower condition beneath it. GlaxoSmithKline has the most among industry and government lead sponsors, with 184.

MeSH D009976 Infections C01
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 310 Phase 1/2 Phase 1/2 110 Phase 2 Phase 2 352 Phase 2/3 Phase 2/3 40 Phase 3 Phase 3 389 Phase 4 Phase 4 343 Not applicable Not applicable 327 Observational Observational 324 Phase 1 Phase 1 310 Phase 1/2 Phase 1/2 110 Phase 2 Phase 2 352 Phase 2/3 Phase 2/3 40 Phase 3 Phase 3 389 Phase 4 Phase 4 343 Not applicable Not applicable 327 Observational Observational 324

Trials per phase

95 of the 2,195 trials are tagged with Orthomyxoviridae Infections itself; the rest are tagged with a narrower condition beneath it.

Get the Orthomyxoviridae Infections report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Orthomyxoviridae Infections trials start? (30)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 216

1997: 1 trials (Observational 1) 1998: 2 trials (Observational 1, Phase 4 1) 1999: 1 trials (Phase 3 1) 2000: 4 trials (Phase 3 3, Phase 2 1) 2001: 7 trials (Phase 3 3, Phase 2 4) 2002: 7 trials (Phase 4 2, Phase 3 3, Phase 2 1, Phase 1/2 1) 2003: 9 trials (Observational 1, Phase 4 4, Phase 3 1, Phase 2/3 1, Phase 2 2) 2004: 28 trials (Observational 7, Not applicable 3, Phase 4 7, Phase 3 4, Phase 2/3 3, Phase 2 3, Phase 1 1) 2005: 59 trials (Observational 3, Not applicable 8, Phase 4 7, Phase 3 14, Phase 2/3 1, Phase 2 12, Phase 1/2 6, Phase 1 8) 2006: 93 trials (Observational 6, Not applicable 7, Phase 4 12, Phase 3 19, Phase 2 27, Phase 1/2 10, Phase 1 12) 2007: 108 trials (Observational 11, Not applicable 10, Phase 4 10, Phase 3 21, Phase 2/3 1, Phase 2 33, Phase 1/2 6, Phase 1 16) 2008: 99 trials (Observational 6, Not applicable 11, Phase 4 13, Phase 3 25, Phase 2/3 2, Phase 2 17, Phase 1/2 5, Phase 1 20) 2009: 216 trials (Observational 33, Not applicable 25, Phase 4 32, Phase 3 36, Phase 2/3 7, Phase 2 60, Phase 1/2 8, Phase 1 15) 2010: 157 trials (Observational 22, Not applicable 18, Phase 4 28, Phase 3 38, Phase 2/3 3, Phase 2 19, Phase 1/2 7, Phase 1 22) 2011: 102 trials (Observational 19, Not applicable 13, Phase 4 21, Phase 3 10, Phase 2/3 3, Phase 2 10, Phase 1/2 3, Phase 1 23) 2012: 116 trials (Observational 8, Not applicable 16, Phase 4 22, Phase 3 23, Phase 2/3 3, Phase 2 9, Phase 1/2 9, Phase 1 26) 2013: 121 trials (Observational 14, Not applicable 16, Phase 4 24, Phase 3 30, Phase 2 18, Phase 1/2 4, Phase 1 15) 2014: 94 trials (Observational 13, Not applicable 11, Phase 4 17, Phase 3 17, Phase 2/3 2, Phase 2 9, Phase 1/2 9, Phase 1 16) 2015: 79 trials (Observational 18, Not applicable 6, Phase 4 16, Phase 3 12, Phase 2 10, Phase 1/2 4, Phase 1 13) 2016: 92 trials (Observational 13, Not applicable 19, Phase 4 15, Phase 3 16, Phase 2/3 2, Phase 2 14, Phase 1/2 1, Phase 1 12) 2017: 81 trials (Observational 18, Not applicable 13, Phase 4 15, Phase 3 10, Phase 2/3 3, Phase 2 9, Phase 1/2 2, Phase 1 11) 2018: 80 trials (Observational 16, Not applicable 14, Phase 4 15, Phase 3 9, Phase 2/3 1, Phase 2 14, Phase 1/2 1, Phase 1 10) 2019: 75 trials (Observational 17, Not applicable 11, Phase 4 13, Phase 3 13, Phase 2 9, Phase 1 12) 2020: 74 trials (Observational 21, Not applicable 20, Phase 4 7, Phase 3 11, Phase 2/3 3, Phase 2 5, Phase 1/2 1, Phase 1 6) 2021: 76 trials (Observational 15, Not applicable 9, Phase 4 18, Phase 3 9, Phase 2/3 1, Phase 2 13, Phase 1/2 3, Phase 1 8) 2022: 96 trials (Observational 17, Not applicable 21, Phase 4 6, Phase 3 16, Phase 2/3 2, Phase 2 12, Phase 1/2 6, Phase 1 16) 2023: 83 trials (Observational 15, Not applicable 19, Phase 4 10, Phase 3 12, Phase 2 9, Phase 1/2 6, Phase 1 12) 2024: 82 trials (Observational 14, Not applicable 19, Phase 4 9, Phase 3 12, Phase 2/3 1, Phase 2 9, Phase 1/2 10, Phase 1 8) 2025: 75 trials (Observational 5, Not applicable 20, Phase 4 10, Phase 3 10, Phase 2/3 1, Phase 2 10, Phase 1/2 4, Phase 1 15)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 64
2025 75
2024 82
2023 83
2022 96
2021 76
2020 74
2019 75
2018 80
2017 81

Showing 10 of 30 earlier years.

Start your 14-day trial Email me all 30 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 80 trials starting in 2026 and about 83 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 28 months from start to primary completion across 90 trials still running at the 2026-10-09 snapshot; registered median of 8 months across 1,738 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Orthomyxoviridae Infections trials in? (8)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 310
Phase 1/2 110
Phase 2 352
Phase 2/3 40
Phase 3 389
Phase 4 343
Not applicable 327
Observational 324

How many Orthomyxoviridae Infections trials are recruiting? (9)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 39
Recruiting 93
Enrolling by invitation 9
Active, not recruiting 47
Completed 1,723

Showing 5 of 9 statuses.

Start your 14-day trial Email me all 9 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Orthomyxoviridae Infections trials? (13)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
GlaxoSmithKline 184
National Institute of Allergy and Infectious Diseases (NIAID) 180
Sanofi Pasteur, a Sanofi Company 117
Novartis Vaccines 61
Seqirus 51

Showing 5 of 13 sponsors.

Start your 14-day trial Email me all 13 sponsors as a PDF

Which drugs are being tested for Orthomyxoviridae Infections? (2)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Oseltamivir 77
Baloxavir Marboxil 17

Interventions as named in the registry (13)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
INFLUENZA VACCINE 69
Fluarix 48
Fluzone 36
FLuMist 29
Influenza Virus Vaccine 26

Showing 5 of 13 interventions.

Start your 14-day trial Email me all 13 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Orthomyxoviridae Infections trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 1,715 143
Atrial fibrillation 808 65
Cerebrovascular accident 697 56
Chronic obstructive pulmonary disease 642 51
Osteoarthritis 629 60

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Orthomyxoviridae Infections? (113)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Influenza A virus infection during pregnancy increases transfer of maternal bloodborne molecules to fetal tissues. Brain, behavior, and immunity 2025 Yes
Mucosal correlates of protection after influenza viral challenge of vaccinated and unvaccinated healthy volunteers. mBio 2024 Yes
Influenza A virus infection disrupts the function of syncytiotrophoblast cells and contributes to adverse pregnancy outcomes. Journal of medical virology 2024 Yes
Efficient symptomatic treatment and viral load reduction for children with influenza virus infection by nasal-spraying Bacillus spore probiotics. Scientific reports 2023 Yes
Human influenza virus infection elicits distinct patterns of monocyte and dendritic cell mobilization in blood and the nasopharynx. eLife 2023 Yes

Showing 5 of 113 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (2)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages